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T he rates of reintubation after pediatric and neo-natal cardiac surgery are approx.  6-9% and 17%,  
respectively [1-3].  Unsuccessful extubation is associ-
ated with a long intensive care unit (ICU) length of stay 
(LOS) and a high rate of mortality [1 , 2].  Therefore,  
adequate respiratory support to prevent the need for 
reintubation is crucial.  Noninvasive ventilation (NIV) 
therapy has been used as a respiratory support in chil-
dren over the past few years [4 , 5].  At our institute,  
NIV is used as the first-line therapy for respiratory sup-
port after pediatric cardiac surgery to avoid intubation,  
because NIV is less invasive compared to mechanical 
ventilation with intubation.
A high-flow nasal cannula (HFNC) is a respiratory 
support device that can deliver heated and humidified 
gas at a high flow rate [6].  It can provide precise frac-
tional oxygen delivery,  mild positive airway pressure,  
washout of nasopharyngeal dead space,  and a reduction 
of airway resistance [4 , 5 , 7 , 8].  HFNC has advantages 
over NIV therapy,  such as ease of use and better 
patient’s comfort [9].  In adult subjects in a randomized 
controlled trial (RCT),  the use of HFNC therapy was 
associated with a lower rate of reintubation compared to 
that of conventional oxygen therapy [10].
NIV therapy for children is sometimes difficult 
because of the patients’ limited compliance and cooper-
ation; thus,  the use of HFNC as an alternative to NIV 
therapy for respiratory support in children is increas-
ing.  However,  only a few RCTs have compared HFNC 
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therapy with NIV therapy in children [11 , 12].  There 
has been no study in which the reintubation rate in 
patients receiving HFNC therapy was compared to that 
in patients receiving NIV therapy after pediatric cardiac 
surgery.
We hypothesized that the reintubation rate would be 
lower in patients receiving HFNC therapy compared to 
patients receiving NIV therapy.  The primary outcome 
of the present study was the reintubation rate within 
48 h after the diagnosis of acute respiratory failure 
(ARF) in a comparison of HFNC and NIV groups.
Patients and Methods
Setting. This study was conducted in a tertiary 
teaching hospital that has 865 beds including 8 beds in 
the pediatric cardiac ICU.
Design and patients. The study was a retrospec-
tive matched-control before-after study.  The Institu-
tional Review Board (IRB) of Okayama University 
Hospital approved the study (no. 1602-505).  The IRB 
did not require individual patient’s written informed 
consent because of the retrospective study design.  
Children aged < 48 months who had received HFNC or 
NIV therapy for ARF after pediatric cardiac surgery 
were included in the study.  HFNC therapy was first 
used in our pediatric cardiac ICU in 2013.  After the 
introduction of HFNC therapy,  the use of NIV therapy 
was replaced by HFNC therapy,  and NIV therapy was 
used only as a bridging therapy to reintubation if HFNC 
therapy was not effective.
Fig . 1 provides the case selection flowchart.  The 
HFNC group was the 35 patients who received HFNC 
therapy during the 2-year period from January 2014 to 
December 2015.  We collected the cases of 35 other 
patients as a matched control group who had received 
NIV therapy after pediatric cardiac surgery during the 
4-year period from January 2009 to December 2012 (the 
NIV group).  The matching parameters were body 
weight (within 3 kg) and risk adjustment for congenital 
heart surgery category 1 (RACHS-1) [13] (less than cat-
egory 2),  which represents the complexity of the pedi-
atric surgery.  Matching priority was given to body 
weight.
Definition of ARF and methods used for NIV ther-
apy and HFNC therapy. The definition of ARF is 
given in Table 1.  In our practice,  HFNC (Optiflow;  
Fisher and Paykel Healthcare,  Auckland,  New Zealand) 
was performed immediately after the diagnosis of 
postextubation ARF.  Flow was commenced at 2 L/kg/
min.  The fraction of inspiratory oxygen (FIO2) was set 
to achieve target oxygen saturation (total repair,  
> 92%; palliative operation,  75-85%).  The temperature 
of gas was set to 37°C with a humidifier.  We selected the 
nasal cannula size according to the child’s weight and 
nasal size.
In our practice,  NIV therapy was also performed 
immediately after a diagnosis of postextubation ARF.  
NIV was delivered by using a fixed tracheal tube as a 
nasal prong,  which was inserted nasally and positioned 
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(2014-2015)(2009-2012)
Children less than 48 month of age (n=355)
Matching 
1. Body weight
2. RACHS-1 category 
Historical matched control group (n=35)
(NIV group)
Children used HFNC for ARF (n=35)
(HFNC group)
Children performed cardiac surgery (n=532)
Children less than 48 month of age (n=804)
Children used NIV for ARF (n=58) 
Children performed cardiac surgery (n=1,108)
HFNC high ﬂow nasal cannula, NIV non invasive ventilation, ARF acute respiratory failure
RACHS-1 Risk adjustment for congenital heart surgery 1
Fig. 1　 The 35 patients who received HFNC therapy during the period from January 2014 to December 2015 at our institute were the 
HFNC group.  For the matched control group,  we collected the cases of 35 patients who had received NIV therapy after pediatric cardiac 
surgery from January 2009 to December 2012.  The matching parameters were body weight and RACHS-1 category.
just before the vocal cord.  Continuous positive airway 
pressure (CPAP) was delivered by using a ventilator 
(Servo I,  MAQUET Holding,  Rastat,  Germany).  The 
FIO2 was set to achieve target oxygen saturation (total 
repair,  > 92%; palliative operation,  75-85%).  The CPAP 
was set to 10 cmH2O.
If failure occurred with these treatments,  NIV ther-
apy or tracheal intubation and invasive mechanical 
ventilation were initiated based on the clinical judgment 
of the physician.  Treating physicians conducted reintu-
bation on the basis of clinical signs: increased respira-
tory rate,  worsening gas exchange,  and patient intoler-
ance.  These criteria for reintubation were unchanged 
during the two study periods.
Data collection. We collected the patients’ data 
from their electronic healthcare records including data 
for age,  body weight,  gender,  RACHS-1 category,  
baseline vital signs,  reintubation rates within 48 h and 
within 28 days after the diagnosis of ARF,  and the ICU 
LOS.
The duration of mechanical ventilation was defined 
as the period since the commencement of mechanical 
ventilation after cardiac surgery until extubation.  The 
attending physician decided the uses of sedative drugs 
in both the NIV and HFNC groups according to the 
patient’s condition.
Statistical analysis. Continuous data are expressed 
as medians and their interquartile range (IQR) when the 
data had a non-normal distribution.  Categorical data 
are presented as percentages.  McNemar’s test was used 
to compare reintubation rates within 48 h and within 28 
days after the diagnosis of ARF,  and the Wilcoxon 
signed-rank test was used for the ICU LOS data.  We 
used a logistic regression model to adjust for the patient 
age to investigate the risk of reintubation within 48 h 
and 28 days between the NIV and HFNC groups.  Two-
tailed p-values < 0.05 were considered significant.  All 
statistical analyses were performed using statistical soft-
ware (JMP® ver. 12; SAS,  Cary,  NC,  USA).
Results
Patient population. Table 2 summarizes the clin-
ical characteristics and baseline vital signs of the chil-
dren in the HFNC group and NIV group.  There was no 
significant difference between the two groups in body 
weight,  RACHS-1 category,  duration of mechanical 
ventilation,  or baseline vital signs.  The patients in the 
HFNC group were significantly younger (median 3 
months,  IQR 1.0-9.0) than those in the NIV group 
(median 1 months,  IQR 0-5.0) (p = 0.01).  The median 
settings of the HFNC group were FIO2 of 0.5 (IQR:  
0.3-0.52) and flow rate of 2.1 (1.7-2.3) L/kg/min,  and 
those of the NIV group were FIO2 of 0.5 (0.21-0.8) and 
CPAP of 10 (8-10) cmH2O.
The percentage of sedative drug use in the HFNC 
group was 49% (dexmedetomidine 37%,  dexmedeto-
midine + morphine 6%,  morphine 3%,  and fentanyl 
3%) and that in the NIV group was 49% (dexmedeto-
midine 20%,  morphine 23%,  dexmedetomidine + fen-
tanyl 3%,  and dexmedetomidine + midazolam 3%) 
(p = 0.81).
Outcomes. Table 3 shows the results of the uni-
variate analysis of the outcome data of the HFNC and 
NIV groups.  The reintubation rate within 48 h after the 
diagnosis of ARF in the HFNC group tended to be 
lower than that in the NIV group (3% vs. 17%,  p= 0.06),  
but not significantly so.  We performed a logistic regres-
sion to adjust for the age difference between the two 
groups,  and the results revealed that HFNC therapy 
was an independent negative predictor for reintubation 
within 48 h: adjusted odds ratio (95% confidence inter-
val) 0.08 (0.002-0.6),  p= 0.01.  The reasons for reintuba-
tion within 48 h after the diagnosis of ARF were cardiac 
and respiratory support (n = 1) in the HFNC group and 
cardiac and respiratory support (n = 3) and respiratory 
support (n = 3) in the NIV group.  Reintubation was 
performed after bridging with NIV therapy in one 
patient in the HFNC group.
The reintubation rate within 28 days after the diag-
nosis of ARF was significantly lower in the HFNC group 
compared to the NIV group (3% vs. 26%,  p= 0.04).  The 
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Table 1　 Deﬁnition of ARF
Tachypnea RR＞50 breath per min (＜1 year old)
RR＞40 breath per min (1-4 years old)
Hypoxemia SaO2 ＜92% (Total repair)
SaO2 ＜75% (Palliative operation)
Hypercapnia PaCO2 ＞50 mmHg
Increased work of
breathing Using accessory respiratory muscle
ARF is deﬁned by at least one of the criteria. 
ARF,  acute respiratory failure; RR,  respiratory rate; SaO2,  satura-
tion of arterial oxygen; PaCO2,  partial pressure of arterial carbon 
dioxide.
reasons for reintubation between 48 h and 28 days after 
the ARF diagnosis in the NIV group were cardiac and 
respiratory support (n = 2) and diaphragmatic paralysis 
(n = 1).
Table 4 lists the results of the logistic regression.  
After adjustment of age,  HFNC therapy was an inde-
pendent negative predictor for reintubation within both 
48 h and 28 days.
The ICU LOS in the HFNC group (median 10 days,  
IQR 7-17 days) was significantly shorter than that in the 
NIV group (median 17 days,  IQR 11-32 days,  p=0.009).
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Table 2　 Main clinical characteristics and baseline vital signs of the HFNC and NIV groups
Variables HFNC group (n＝35) NIV group (n＝35) p Value
Body weight (kg,  IQR) 3.9 (2.9-5.5) 3.4 (2.7-4.8) 0.14
RACHS-1 category 3 (2-4) 3 (3-4) 0.09
Age (months,  IQR) 3 (1.0-9.0) 1 (0-5.0) 0.01
MV time (h,  IQR) 75 (7-171) 93.5 (40-242) 0.23
Palliative surgery (%) 40 51 0.33
CPB (%) 80 82 0.75
CPB time (h,  IQR) 110 (69-137) 119 (81-153) 0.37
Operative time (min,  IQR) 192 (126-243) 216 (167-285) 0.31
Blood loss (ml,  IQR) 18 (0-38) 30 (5-50) 0.14
Duration of HFNC (h,  IQR) 43 (20-64) － －
Duration of NIV (h,  IQR) － 38 (22-72) －
Time to diagnosis of ARF after extubation (h,  IQR) 4 (0-4) 3.5 (0-4) 0.49
RR (breaths/min,  IQR) 43 (33-55) 39 (32-50) 0.47
PaCO2 (mmHg,  IQR) 45.7 (40.1-53.2) 49.1 (44.6-56.1) 0.16
SaO2 (%,  IQR) 89.9 (76.9-96.4) 81.2 (70.4-97.0) 0.36
SBP (mmHg,  IQR) 87 (78-98) 86 (75-100) 0.55
HR (bpm,  IQR) 141 (119-155) 142 (132-160) 0.16
HFNC,  high-ﬂow nasal cannula; NIV,  noninvasive ventilation; IQR,  interquartile range; RACHS-1,  Risk adjustment for congenital heart 
surgery 1; MV,  Mechanical ventilation; CPB,  cardiopulmonary bypass; RR,  respiratory rate; PaCO2,  partial pressure of arterial carbon 
dioxide; SaO2,  arterial oxygen saturation; SBP,  systolic blood pressure; HR,  heart rate.
Table 3　 Univariate analysis of outcome data
Outcomes HFNC group (n＝35) NIV group (n＝35) p Value
Reintubation within 48 h n (%) 1 (3) 6 (17) 0.06
Reintubation within 28 days n (%) 1 (3) 9 (26) 0.04
ICU LOS (days,  IQR) 10 (7-17) 17 (11-32) 0.009
HFNC,  high-ﬂow nasal cannula; NIV,  noninvasive ventilation; IQR,  interquartile range; LOS,  length of stay.
Table 4　 Logistic regression of outcome data
Variable OR Lower 95% CI Upper 95% CI p Value
48 h reintubation rate
HFNC 0.08 0.003 0.63 0.01
Age 0.93 0.85 1.01 0.06
28 days reintubation rate
HFNC 0.08 0.006 0.98 0.04
Age 0.93 0.86 1.00 0.06
OR,  odds ration; CI,  conﬁdential interval; HFNC,  high ﬂow nasal cannula.
Discussion
This is the first study to compare the rate of reintu-
bation after the diagnosis of ARF in patients receiving 
NIV therapy to that in patients receiving HFNC therapy 
for postextubation ARF after pediatric cardiac surgery.  
The results of a univariate analysis demonstrated that 
although the reintubation rate within 48 h after the 
diagnosis of ARF was not significantly different between 
the HFNC and NIV groups,  the reintubation rate 
within 28 days after the ARF diagnosis was significantly 
lower in the HFNC group compared to the NIV group.
In the NIV group,  the reintubation rates within 48 h 
and within 28 days after the diagnosis of ARF were 17% 
and 26%,  respectively.  In past studies,  the reintuba-
tion rates in patients who received NIV therapy ranged 
from 20% to 35% [14-16].  The rate of reintubation in 
the patients who received NIV therapy in our study is 
similar to these reported rates.
The rate of reintubation within 28 days after the ARF 
diagnosis was low in the present HFNC group.  This 
might be due to differences in the characteristics of the 
devices used in the two groups.  A previous study esti-
mated that the positive pressure delivered by HFNC 
therapy (2 L/kg/min) was 4-6 cmH2O [17].  HFNC also 
provides a wash-out of anatomical dead space and then 
reduces the work of breathing.  The CPAP level in our 
NIV group was 10 cmH2O.  However,  NIV increases 
dead space.  To compensate for the increased dead 
space,  more minute ventilation will be needed and this 
will increase the work of breathing.  These differences 
might have caused the difference in the rate of reintuba-
tion between the present HFNC and NIV groups.
Two retrospective studies showed that HFNC ther-
apy might reduce the need for intubation in infants with 
bronchiolitis and children with respiratory distress 
[18 , 19].  Our present finding that HFNC therapy was 
associated with a low reintubation rate is concordant 
with the results of those studies.  In addition,  our pre-
vious study demonstrated a beneficial physiological 
impact of HFNC on patients with ARF after pediatric 
surgery [20].  We thus hypothesized that HFNC could 
prevent ARF after pediatric cardiac surgery,  and an 
intervention study is now underway at our institute 
[21].
Limitations. This was a retrospective study.  We 
compared the rate of reintubation in the HFNC group to 
that in a historical control NIV group.  However,  our 
clinical methods for respiratory support and reintuba-
tion did not change during the two study periods.  In 
addition,  we included patients with different character-
istics and conditions (age,  cyanosis,  type of operation).  
We therefore matched the body weight and RACHS-1 
category between the 2 groups.  This process could 
reduce the issues related to different patient popula-
tions,  but there might be unmatched baseline differ-
ences after the matching process which might have 
affected our results.  Among these baseline differences,  
age was associated with reintubation after pediatric sur-
gery in another study [22].  We thus conducted a post 
hoc adjustment of age difference between the two 
groups using a logistic method.  The results showed that 
HFNC therapy was still an independent negative pre-
dictor after the adjustment for patient age.
The NIV method using a fixed tracheal tube as a 
nasal prong [23] is not commonly used compared to the 
mask method,  and thus the generalization of our results 
is limited.
In conclusion,  HFNC might be associated with a low 
rate of reintubation in children with ARF after cardiac 
surgery.
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